CXCR2 has significant pro-tumor functions, where increased CXCR2 expression is associated with poorer patient prognosis, as shown by studies on acute myeloid leukemia [101], invasive ductal breast cancer [102], colorectal cancer [103], esophageal cancer [104], gastric cancer [16,17,105,106], intrahepatic cholangiocellular carcinoma [107], laryngeal squamous cell carcinoma [108], lung adenocarcinoma [109], non-small cell lung cancer [91], ovarian cancer [110,111], pancreatic ductal adenocarcinoma [112]. This evidence concerns the gene CXCR2 and ovarian cancer.